April 07, 2026

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Conexiant

April 07, 2026

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Conexiant

April 06, 2026

Masters Athletes Present Unique CV Findings

Joint clinical consensus outlines evaluation and management considerations for arrhythmias, coronary atherosclerosis, aortic dilatation, myocardial fibrosis, and related findings in older competitive athletes.

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 06, 2026

Deprescribing Seen in T2D Care

Researchers examine medication changes in practices with lifestyle medicine access

Conexiant

April 03, 2026

Acoramidis Linked to Lower Mortality Through 54 Months

Early treatment was associated with sustained reductions in mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy

Conexiant

April 02, 2026

ACC/AHA Consensus Sets Tricuspid Program Standards

Multisociety document outlines operator, institutional, and registry requirements as transcatheter tricuspid therapies expand

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

April 01, 2026

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

Conexiant

April 01, 2026

Tirzepatide Linked to Lower Cardiorenal Events

Researchers evaluate expanded six-component outcome in high-risk patients with diabetes

Conexiant